Myelodysplastic Syndrome
News
Novel inhibitor proves ‘potent’ in hematologic malignancies
BOSTON—A pair of preclinical studies suggest the FLT3/BTK inhibitor CG’806 is active in a range of hematologic malignancies. In one of the...
News
Study shows similar outcomes with RIC and MAC in MDS
Results of a phase 3 trial revealed similar outcomes in patients who underwent allogeneic hematopoietic stem cell transplant (HSCT) to treat...
From the Journals
FDA boxed warning leads to drop off in use of ESAs
The FDA warning language was linked with a sharp decrease in use of erythropoietin-stimulating agents in colorectal, breast, and lung cancer...
News
Role of TET2 in hematologic malignancies
New research appears to explain how TET2 mutations increase the risk of hematologic malignancies. In studying mouse models and patient samples,...
Conference Coverage
MDS genetic analysis identifies allogeneic HSCT candidates
NEW YORK – What role might genetic mutation analysis of patients with MDS play in routine practice?
Conference Coverage
Extended maraviroc helps prevent graft-versus-host disease
ORLANDO – Use of maraviroc for 90 days is safe and effective for prevention of graft-versus-host disease in allogeneic stem cell transplantation...
News
Polycythemia vera test detects JAK2 V617F/G1849T mutation
The ipsogen JAK2 RGQ PCR Kit has been given marketing authorization by the Food and Drug Administration.
Conference Coverage
Myelofibrosis therapies moving beyond ruxolitinib
ORLANDO – A number of agents in clinical trials show promise for treatment of myelofibrosis.
Guidelines
NCCN myelofibrosis guideline: Patient voice is key
ORLANDO – Treatment decisions in myelofibrosis patients are complex and require patient input. A new treatment guideline from the NCCN addresses...
News
Protein may prevent transformation from MDS to AML
The protein p300 may prevent the transformation from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML), according to research...
Conference Coverage
NCCN: Myelofibrosis guideline is first in series on MPNs
ORLANDO – A guideline published in December 2016 for the diagnostic work-up of myeloproliferative neoplasms and for the management of...